Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Immunogenetics ; 51(4-5): 314-25, 2000 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10803844

RESUMO

The human major histocompatibility complex (MHC) class I gene, HLA-B27, is a strong risk factor for susceptibility to a group of disorders termed spondyloarthropathies. Rodents that express HLA-B27 develop spondyloarthropathies, implicating HLA-B27 in the etiology of these disorders. To determine whether an HLA-B27-like molecule was associated with spondyloarthropathies in nonhuman primates, we analyzed the MHC class I cDNAs expressed in a cohort of rhesus macaques that developed reactive arthritis after an outbreak of shigellosis. We identified several cDNAs with only limited sequence similarity to HLA-B27. Interestingly, one of these MHC molecules had a B pocket identical to that of HLA-B39. Pool sequencing of radiolabeled peptides bound by this molecule demonstrated that, like HLA-B27 and HLA-B39, it could bind peptides with arginine at the second position. However, extensive analysis of the MHC class I molecules in this cohort revealed no statistically significant association between any particular MHC class I allele and susceptibility to reactive arthritis. Furthermore, none of the rhesus MHC class I molecules bore a strong resemblance to HLA-B27, indicating that reactive arthritis can develop in this animal model in the absence of an HLA-B27-like molecule. Surprisingly, there was a statistically significant association between the rhesus macaque MHC A locus allele, Mamu-A*12, and the absence of reactive arthritis following Shigella infection.


Assuntos
Artrite Reativa/epidemiologia , Disenteria Bacilar/complicações , Genes MHC Classe I , Antígeno HLA-B27/genética , Antígenos de Histocompatibilidade Classe I/genética , Shigella flexneri , Alelos , Sequência de Aminoácidos , Animais , Artrite Reativa/genética , Artrite Reativa/imunologia , Estudos de Coortes , Suscetibilidade a Doenças , Feminino , Antígenos HLA-B/genética , Antígeno HLA-B39 , Imunidade Inata , Macaca mulatta , Masculino , Dados de Sequência Molecular , Homologia de Sequência de Aminoácidos
2.
Transplantation ; 68(4): 545-54, 1999 Aug 27.
Artigo em Inglês | MEDLINE | ID: mdl-10480415

RESUMO

BACKGROUND: An anti-CD3 antibody that reduces cytokine release syndrome (CRS) while maintaining immunosuppression would be a major advance in the treatment of acute allograft rejection. A humanized (Hu) anti-CD3 IgG2 Ab, HuM291 gamma2 M3 (HuM291; Protein Design Labs, Inc., Mountain View, CA), was engineered with mutations in the upper CH2 region of the Fc domain. The mutations were intended to reduce affinity for Fcgamma receptors, thought to be relevant to CRS. METHODS: In vitro studies using chimpanzee peripheral blood mononuclear cells (PBMCs) were conducted to characterize HuM291 and to establish an animal model. A multidose study was conducted in chimpanzees to evaluate the safety, pharmacokinetics, immunomodulatory activity, and immunogenicity of HuM291, when administered at doses ranging from 0.1 to 10 mg. RESULTS: HuM291 bound to and effectively downmodulated CD3 from chimpanzee PBMCs and stimulated substantially less cytokine secretion and proliferation of chimpanzee PBMCs compared with OKT3 (Orthoclone OKT3; Ortho Pharmaceutical Corp., Raritan, NJ). Multiple doses of HuM291 (0.1, 1.0, or 10 mg/dose) were not associated with adverse events, signs of toxicity, or CRS, despite cytokine release. HuM291 exhibited a long elimination t1/2 (81.5 hr) and, after three 10-mg doses, sustained serum concentrations > 1000 ng/ml were maintained for 1 week. Multiple 10-mg doses induced complete depletion of circulating CD2+CD3+ T cells for up to 10 days after the last dose; T cells recovered by Day 28. Anti-HuM291 Abs were observed in only 4 of 12 animals and were transient in 2 of those animals. CONCLUSIONS: In vitro, HuM291 is substantially less mitogenic than OKT3. In chimpanzees, HuM291 effectively depleted peripheral T cells without eliciting clinical signs of CRS, and recovered T cells were functionally normal.


Assuntos
Anticorpos Monoclonais/farmacologia , Soro Antilinfocitário/farmacologia , Complexo CD3 , Depleção Linfocítica/métodos , Linfócitos T/imunologia , Animais , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/genética , Especificidade de Anticorpos , Soro Antilinfocitário/administração & dosagem , Soro Antilinfocitário/genética , Complexo CD3/metabolismo , Feminino , Humanos , Técnicas In Vitro , Ativação Linfocitária , Contagem de Linfócitos , Masculino , Camundongos , Muromonab-CD3/farmacologia , Mutação , Pan troglodytes , Engenharia de Proteínas , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/imunologia , Proteínas Recombinantes de Fusão/farmacologia
3.
Am J Vet Res ; 47(8): 1671-3, 1986 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-3752674

RESUMO

Fenbendazole given at the rate of 2.5 g/kg of feed for 3 days had 100% efficacy against 4th-stage Ascaris suum larvae in 8 pigs. Eight control pigs had a total of 108 A suum. In 6 pigs infected 3 times with 3rd-stage A suum larvae and treated with fenbendazole after the larvae molted to the 4th stage, the challenge exposure-derived population was decreased by 64%. Similar sequential infections in 6 pigs similarly infected, but not treated with fenbendazole, decreased the challenge exposure-derived population by 98%; however, developing and/or adult worms from the vaccinating infections were present.


Assuntos
Ascaríase/veterinária , Ascaris/efeitos dos fármacos , Benzimidazóis/uso terapêutico , Fenbendazol/uso terapêutico , Doenças dos Suínos/tratamento farmacológico , Animais , Ascaríase/tratamento farmacológico , Ascaríase/imunologia , Feminino , Fenbendazol/farmacologia , Imunidade Inata , Larva/efeitos dos fármacos , Masculino , Suínos
4.
Appl Opt ; 21(21): 3896-902, 1982 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-20396337

RESUMO

This is one of two papers which describe the development and performance of a very stable and rugged etalon designed for use in the Fabry-Perot interferometer, one of the instruments of the NASA Dynamics Explorer satellite mission, and which will obtain global measurements of the thermospheric and mesospheric wind and temperature with an accuracy of aporoximately 10 m/sec. The etalon consists of two flat plates of fused silica, with spacers constructed of Zerodur (a polycrystalline glass ceramic of extremely low expansion coefficient) which are cemented together using cyanoacrylic adhesives. This provides adequate mechanical integrity and stability for any space flight application and has a thermal expansion coefficient of the etalon cavity of <10(-7)/ degrees C.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...